Adamantane-based dendrons for trimerization of the therapeutic P140 peptide

Biomaterials

Volumn 35, Issue 26, 2014, Pages 7553-7561

  Lamanna, Giuseppe ^a   Grillaud, Maxime ^a   Macri, Christophe ^a   Chaloin, Olivier ^a   Muller, Sylviane ^a   Bianco, Alberto ^a  

^a INSTITUT DE BIOLOGIE MOLÉCULAIRE ET CELLULAIRE   (France)

Author keywords

Adamantane; C3 symmetry; Dendrimers; Dendrons; HSPA8 protein; P140 peptide

Indexed keywords

BINDING ENERGY; CHEMICAL REACTIONS; DENDRIMERS; MAMMALS; MEDICAL APPLICATIONS; OLIGOMERS;

ADAMANTANE DERIVATIVES; ADAMANTANES; BINDING AFFINITIES; BIOMEDICAL APPLICATIONS; DENDRONS; FOLDING PROPERTIES; SCRAMBLED SEQUENCE; SPATIAL CONFORMATION;

PEPTIDES;

ADAMANTANE; ADAMANTANE DERIVATIVE; BIOTIN; FUNCTIONAL GROUP; HEAT SHOCK COGNATE PROTEIN 70; MOLECULAR SCAFFOLD; MONOMER; P140 PEPTIDE; PHOSPHOPEPTIDE; POLYMER; UNCLASSIFIED DRUG; DENDRIMER; DRUG CARRIER; HSPA8 PROTEIN, MOUSE; PEPTIDE FRAGMENT; SPLICEOSOMAL PEPTIDE P140;

AMINO ACID SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BINDING AFFINITY; BIOTINYLATION; CLICK CHEMISTRY; CONFORMATION; CONJUGATE; CONTROLLED STUDY; COVALENT BOND; DENDRITE; DISEASE ACTIVITY; DOWN REGULATION; FEMALE; IN VITRO STUDY; IN VIVO STUDY; MOLECULAR RECOGNITION; MOUSE; MURPHY ROTHS LARGE LYMPHOPROLIFERATIVE MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN FOLDING; PROTEIN POLYMERIZATION; PROTEIN PROTEIN INTERACTION; RECEPTOR BINDING; SINGLE DRUG DOSE; SOLUBILITY; STEREOSPECIFICITY; SYNTHESIS; ANIMAL; CHEMISTRY; HUMAN; LUPUS ERYTHEMATOSUS, SYSTEMIC; METABOLISM;

MUS;

ADAMANTANE; ANIMALS; BIOTIN; DENDRIMERS; DRUG CARRIERS; FEMALE; HSC70 HEAT-SHOCK PROTEINS; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MICE, INBRED MRL LPR; PEPTIDE FRAGMENTS;

EID: 84902536282     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2014.05.017     Document Type: Article

References (53)

1. Kesharwani P., Jain K., Jain N.K. Dendrimer as nanocarrier for drug delivery. Prog Polym Sci 2014, 39:268-307.
2. Mignani S., El Kazzouli S., Bousmina M., Majoral J.P. Dendrimer space concept for innovative nanomedicine: a futuristic vision for medicinal chemistry. Prog Polym Sci 2013, 38:993-1008.
3. Khandare J., Calderon M., Dagia N.M., Haag R. Multifunctional dendritic polymers in nanomedicine opportunities and challenges. Chem Soc Rev 2012, 41:2824-2848.
4. Mintzer M.A., Grinstaff M.W. Biomedical applications of dendrimers a tutorial. Chem Soc Rev 2011, 40:173-190.
5. Medina S.H., El-Sayed M.E.H. Dendrimers as carriers for delivery of chemotherapeutic agents. Chem Rev 2009, 109:3141-3157.
6. Gillies E.R., Fréchet J.M.J. Dendrimers and dendritic polymers in drug delivery. Drug Discov Today 2005, 10:35-43.
7. Svenson S., Tomalia D.A. Dendrimers in biomedical applications-reflections on the field. Adv Drug Deliv Rev 2005, 57:2106-2129.
8. Cloninger M.J. Biological applications of dendrimers. Curr Opin Chem Biol 2002, 6:742-748.
9. Newkome G.R., Schreiner C. Dendrimers serived from 1 → 3 branching motifs. Chem Rev 2010, 110:6338-6442.
10. Newkome G.R., Yao Z., Baker G.R., Gupta V.K. Cascade molecules: a new approach to micelles. JOrg Chem 1985, 50:2003-2004.
11. Rolland O., Turrin C.O., Caminade A.M., Marjoral J.P. Dendrimers and nanomedicine: multivalency in action. New J Chem 2009, 33:1809-1824.
12. Woller E.K., Cloninger M.J. The lectin-binding properties of six generations of mannose-functionalized dendrimers. JOrg Lett 2002, 4:7-10.
13. Schüll C., Frey H. Grafting of hyperbranched polymers: from unusual complex polymer topologies to multivalent surface functionalization. Polymer 2013, 54:5443-5455.
14. Zhao D., Ong S.M., Yue Z., Jiang Z., Toh Y.C., Khan M., et al. Dendrimer hydrazides as multivalent transient inter-cellular linkers. Biomaterials 2008, 29:3693-3702.
15. Badjic J.D., Nelson A., Cantrill S.J., Turnbull W.B., Stoddart J.F. Multivalency and cooperativity in supramolecular chemistry. Acc Chem Res 2005, 38:723-732.
16. Mulder A., Huskens J., Reinhoudt D.N. Multivalency in supramolecular chemistry and nanofabrication. Org Biomol Chem 2004, 2:3409-3424.
17. Varga N., Sutkeviciute I., Ribeiro-Viana R., Berzi A., Ramdasi R., Daghetti A., et al. Amultivalent inhibitor of the DC-SIGN dependent uptake of HIV-1 and dengue virus. Biomaterials 2014, 35:4175-4184.
18. Zhang Z., Ali M.M., Eckert M.A., Kang D.K., Chen Y.Y., Sender L.S., et al. Apolyvalent aptamer system for targeted drug delivery. Biomaterials 2013, 34:9728-9735.
19. Huskens J. Multivalent interactions at interfaces. JCurr Opin Chem Biol 2006, 10:537-543.
20. Mammen M., Choi S.K., Whitesides G.M. Polyvalent interactions in biological systems: implications for design and use of multivalent ligands and inhibitors. Angew Chem Int Ed 1998, 37:2754-2794.
21. Michiue H., Sakurai Y., Kondo N., Kitamatsu M., Bin F., Nakajima K., et al. The acceleration of boron neutron capture therapy using multi-linked mercaptoundecahydrododecaborate (BSH) fused cell-penetrating peptide. Biomaterials 2014, 35:3396-3405.
22. Eggimann G.A., Buschor S., Darbre T., Reymond J.L. Convergent synthesis and cellular uptake of multivalent cell penetrating peptides derived from Tat, Antp, pVEC, TP10 and SAP. Org Biomol Chem 2013, 11:6717-6733.
23. Ayala R., Zhang C., Yang D., Hwang Y., Aung A., Shroff S.S., et al. Engineering the cell-material interface for controlling stem cell adhesion, migration, and differentiation. Biomaterials 2011, 32:3700-3711.
24. Kiessling L.L., Gestwicki J.E., Strong L.E. Synthetic multivalent ligands as probes of signal transduction. Angew Chem Int Ed 2006, 45:2348-2368.
25. Gao J., Chen K., Luong R., Bouley D.M., Mao H., Qiao T., et al. Anovel clinically translatable fluorescent nanoparticle for targeted molecular imaging of tumors in living subjects. Nano Lett 2012, 12:281-286.
26. Welsh D.J., Smith D.K. Comparing dendritic and self-assembly strategies to multivalency-RGD peptide-integrin interactions. Org Biomol Chem 2011, 9:4795-4801.
27. Graef I.A., Holsinger L.J., Diver S., Schreiber S.L., Crabtree G.R. Proximity and orientation underlie signaling by the non-receptor tyrosine kinase ZAP70. EMBO J 1997, 16:5618-5628.
28. Carrithers M.D., Lerner M.R. Synthesis and characterization of bivalent peptide ligands targeted to G-protein-coupled receptors. Chem Biol 1996, 3:537-542.
29. Gibson S.E., Castaldi M.P. C3 Symmetry: molecular design inspired by nature. Angew Chem Int Ed 2006, 45:4718-4720.
30. Fournel S., Wieckowski S., Sun W., Trouche N., Dumortier H., Bianco A., et al. C3-symmetric peptide scaffolds are functional mimetics of trimeric CD40L. Nat Chem Biol 2005, 1:377-382.
31. Rao J., Lahiri J., Isaacs L., Weis R.M., Whitesides G.M. Atrivalent system from vancomycin·d-Ala-d-Ala with higher affinity than avidin·biotin. Science 1998, 280:708-711.
32. Pannier N., Maison W. Rigid C3-symmetric scaffolds based on adamantane. Eur J Org Chem 2008, 1278-1284.
33. Nasr K., Pannier N., Frangioni J.V., Maison W. Rigid multivalent scaffolds based on adamantane. JOrg Chem 2008, 73:1056-1060.
34. Maison W., Frangioni J.V., Pannier N. Synthesis of rigid multivalent scaffolds based on adamantane. Org Lett 2004, 6:4567-4569.
35. Wanka L., Iqbal K., Schreiner P.R. The lipophilic bullet hits the targets: medicinal chemistry of adamantane derivatives. Chem Rev 2013, 113:3516-3604.
36. Fleck C., Franzmann E., Claes D., Rickert A., Maison W. Synthesis of functionalized adamantane derivatives: (3+1)-scaffolds for applications in medicinal and material chemistry. Synthesis 2013, 45:1452-1461.
37. Reichert V.R., Mathias L.J. Expanded tetrahedral molecules from 1,3,5,7-tetraphenyladarnantane. Macromolecules 1994, 27:7015-7023.
38. Lamanna G., Smulski C.R., Chekkat N., Estieu-Gionnet K., Guichard G., Fournel S., et al. Multimerization of an apoptogenic TRAIL-mimicking peptide by using adamantane-based dendrons. Chem Eur J 2013, 19:1762-1768.
39. Lamanna G., Russier J., Dumortier H., Bianco A. Enhancement of anti-inflammatory drug activity by multivalent adamantane-based dendrons. Biomaterials 2012, 33:5610-5617.
40. Pavet V., Beyrath J., Pardin C., Morizot A., Lechner M.C., Briand J.-P., et al. Multivalent DR5 peptides activate the TRAIL death pathway and exert tumoricidal activity. Cancer Res 2010, 70:1101-1110.
41. Franzmann E., Khalil F., Weidmann C., Schröder M., Rohnke M., Janek J., et al. Abiomimetic principle for the chemical modification of metal surfaces: synthesis of tripodal catecholates as analogues of siderophores and mussel adhesion proteins. Chem Eur J 2011, 17:8596-8603.
42. Humblet V., Misra P., Bhushan K.R., Nasr R., Ko Y.S., Tsukamoto T., et al. Multivalent scaffolds for affinity maturation of small molecule cell surface binders and their application to prostate tumor targeting. JMed Chem 2009, 52:544-550.
43. Monneaux F., Lozano J.M., Patarroyo M.E., Briand J.P., Muller S. Tcell recognition and therapeutic effect of a phosphorylated synthetic peptide of the 70K snRNP protein administered in MR/lpr mice. Eur J Immunol 2003, 33:287-296.
44. Page N., Gros F., Schall N., Décossas M., Bagnard D., Briand J.P., et al. HSC70 blockade by the therapeutic peptide P140 affects autophagic processes and endogenous MHCII presentation in murine lupus. Ann Rheum Dis 2011, 70:837-843.
45. Schall N., Page N., Macri C., Chaloin O., Briand J.P., Muller S. Peptide-based approaches to treat lupus and other autoimmune diseases. JAutoimmun 2012, 39:143-153.
46. Muller S., Monneaux F., Schall N., Rashkov R.K., Oparanov B.A., Wiesel P., et al. Spliceosomal peptide P140 for immunotherapy of systemic lupus erythematosus: results of an early phase II clinical trial. Arthritis Rheum 2008, 58:3873-3883.
47. Zimmer R., Scherbarth H.R., Rillo O.L., Gomez-Reino J.J., Muller S. Lupuzor/P140 peptide in patients with systemic lupus erythematosus: a randomised, double-blind, placebo-controlled phase IIb clinical trial. Ann Rheum Dis 2013, 72:1830-1835.
48. Page N., Schall N., Strub J.M., Quinternet M., Chaloin O., Décossas M., et al. The spliceosomal phosphopeptide P140 controls the lupus disease by interacting with the HSC70 protein and via a mechanism mediated by γδ T cells. PLoS One 2009, 4:e5273.
49. Monneaux F., Parietti V., Briand J.-P., Muller S. Importance of spliceosomal RNP1 motif for intermolecular T-B cell spreading and tolerance restoration in lupus. Arthritis Res Ther 2007, 9:R111.
50. Grillaud M., Russier J., Bianco A. Polycationic adamantane-based dendrons of different generations display high cellular uptake without triggering cytotoxicity. JAm Chem Soc 2014, 136:810-819.
51. Freeman B.C., Myers M.P., Schumacher R., Morimoto R.I. Identification of a regulatory motif in Hsp70 that affects ATPase activity, substrate binding and interaction with HDJ-1. EMBO J 1995, 14:2281-2292.
52. Lamanna G., Russier J., Ménard-Moyon C., Bianco A. HYDRAmers: design, synthesis and characterization of different generation novel Hydra-like dendrons based on multifunctionalized adamantane. Chem Commun 2011, 47:8955-8957.
53. Stricher F., Macri C., Ruff M., Muller S. HSPA8/HSC70 chaperone protein: structure, function, and chemical targeting. Autophagy 2013, 9:1937-1954.